Bronnen:
- Gootjes EC, Bakkerus L, Ten Tije AJ, et al. The value of tumour debulking for patients with extensive multi-organ metastatic colorectal cancer. Eur J Cancer. 2018;103:160-4.,ORCHESTRA. https://dccg.nl/trial/orchestra.,clinicaltrials.gov, NCT01792934. ,Hadden WJ, de Reuver PR, Brown K, et al. Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford). 2016;18:209-20. ,Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-59. ,Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-75. ,clinicaltrials.gov, NCT01606098. ,clinicaltrials.gov, NCT02738606.